In pursuit of excellence in scholarly publishing, the Neuroscience editorial team shares valuable insights that are essential for authors, reviewers, and the broader scientific community. Firstly, we emphasize that impactful research is built on rigorous study design and execution. Beyond fundamental methodological safeguards such as randomization and blinded analysis, we highlight the importance of thoughtfully selecting study models, with deliberate attention to biological variables like sex and gender, as well as appropriate nomenclature. Secondly, as technological innovations reshape research landscapes, we advocate for combining methodological rigor with suitable analytical tools to ensure robust data collection and transparent reporting. Thirdly, for manuscripts reaching the revision stage, we frame the response to reviewers as a strategic process that requires objectivity, diplomacy, and evidence-based rebuttals where necessary. Finally, we call for intentional prioritization of inclusivity and diversity across all stages of scientific inquiry - from laboratory collaborations to editorial decisions - and urge stakeholders to actively counteract implicit biases in manuscript evaluation and citation practices. By embedding these principles into the scientific workflow, we argue that the research community can foster not only greater rigor but also a more equitable and innovative scholarly ecosystem.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroscience.2025.03.005 | DOI Listing |
Front Psychiatry
February 2025
Department of Psychology, University of Turin, Turin, Italy.
Background: Affect dynamics, or variations in emotional experiences over time, are linked to psychological health and well-being, with moderate emotional variations indicating good psychophysical health. Given the impact of emotional state on cardiac variability, our objective was to develop a quantitative method to measure affect dynamics for better understanding emotion temporal management in Anorexia Nervosa (AN).
Methods: The study proposed an experimental and methodological approach to evaluate physiological affect dynamics in clinical settings.
Front Psychiatry
February 2025
Department of Child and Adolescent Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain.
Unlabelled: Autism spectrum disorder (ASD) refers to a group of complex neurodevelopmental disorders and is characterized by impaired reciprocal social interaction and communication, as well as the presence of restricted interests and stereotyped and repetitive behaviors. As a complex neurodevelopmental disorder, the phenotype and severity of autism are extremely heterogeneous, with differences from one patient to another. Chromosome microarray (CMA) and fragile X syndrome analyses has been used as a powerful tool to identify new candidate genes for ASD.
View Article and Find Full Text PDFFront Hum Neurosci
February 2025
Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, United States.
The Deep Brain Stimulation (DBS) Think Tank XII was held on August 21st to 23rd. This year we showcased groundbreaking advancements in neuromodulation technology, focusing heavily on the novel uses of existing technology as well as next-generation technology. Our keynote speaker shared the vision of using neuro artificial intelligence to predict depression using brain electrophysiology.
View Article and Find Full Text PDFAlzheimers Res Ther
March 2025
Department of Biomedical Engineering, University of California, Irvine, CA, USA.
Background: Nicotinamide, a form of B3 vitamin, is an NAD precursor that reduces pTau levels via histone deacetylase inhibition in murine models of Alzheimer's disease (AD). A recent phase 2a randomized placebo-controlled trial tested high-dose oral nicotinamide for the treatment of early AD. While nicotinamide demonstrated good safety and tolerability, it did not significantly lower CSF pTau, the primary biomarker endpoint of the study.
View Article and Find Full Text PDFNeurol Ther
March 2025
Department of Human Neurosciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Introduction: Subjects with intellectual disability are usually excluded from clinical trials and there is limited evidence-based guidance for the choice of antiseizure medications in this vulnerable population. The study explored the effectiveness of brivaracetam (BRV) in people with epilepsy and intellectual disability.
Methods: BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST) was a 12-month retrospective, multicenter study including adults prescribed adjunctive BRV.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!